Blood Groups, Blood Banking, Blood Components and Transfusion (NEET PG 2027 - Pathology)	<b>ABO BLOOD GROUP SYSTEM</b><br><br>ABO antigens are carbohydrate structures on RBC surface proteins and lipids, synthesized by polymorphic glycosyltransferases encoded on chromosome 9. All individuals first form the H antigen (core fucosylated glycan). The A allele enzyme adds terminal N-acetylgalactosamine to H antigen - forming A antigen. The B allele enzyme adds terminal galactose - forming B antigen. O allele product is devoid of enzymatic activity - only H antigen expressed. AB individuals express both A and B antigens. Blood group O individuals have the most H antigen. Anti-A and anti-B are naturally occurring IgM isohemagglutinins (preformed without prior sensitization). ABO antigens are present on RBCs, endothelial cells, and some epithelial cells.<br><br><b>ABO BLOOD GROUP TABLE</b><br><br>Group A: antigen A on RBC, anti-B antibody in serum. Group B: antigen B on RBC, anti-A antibody in serum. Group AB: antigens A and B on RBC, no antibody - universal recipient for RBCs. Group O: no A or B antigen on RBC, anti-A and anti-B antibodies - universal donor for RBCs. Universal plasma donor: Group AB (no antibodies). Universal plasma recipient: Group O.<br><br><b>Rh BLOOD GROUP SYSTEM</b><br><br>Rh antigens are proteins (not carbohydrates) on RBC membrane. The D antigen is the most clinically significant - it is the major cause of Rh incompatibility. Rh-positive means D antigen is present. Approximately 85% of population is Rh-positive. Anti-D antibodies are NOT naturally occurring - formed only after sensitization (exposure to Rh-positive RBCs). First sensitization produces IgM, subsequent exposures produce IgG. IgG crosses the placenta - causes hemolytic disease of fetus and newborn (HDFN). Other Rh antigens: C, c, E, e (minor clinical importance). Rh-negative recipients should receive Rh-negative blood (risk of immunization to D antigen is approximately 30%). Prophylactic anti-D immunoglobulin given to Rh-negative mothers at 28 weeks and within 72 hours of delivery of Rh-positive baby.<br><br><b>OTHER BLOOD GROUP SYSTEMS</b><br><br>Kell system: K antigen - clinically significant, important in sickle cell disease patients. Duffy system: Fy antigens - Duffy-null RBCs resistant to Plasmodium vivax invasion. Kidd system: Jk antigens - important in delayed hemolytic reactions. Lewis system: Le antigens on plasma glycoproteins adsorbed onto RBCs - carbohydrate antigens. MNS system: M, N, S, s antigens.<br><br><b>BLOOD BANKING - PRETRANSFUSION TESTING</b><br><br>1. ABO and Rh typing: forward grouping (patient cells + antisera) and reverse grouping (patient serum + known RBCs). 2. Antibody screen (indirect Coombs test): detects unexpected alloantibodies in recipient serum. 3. Crossmatch: major crossmatch tests recipient serum against donor RBCs - detects incompatibility. Minor crossmatch tests donor plasma against recipient RBCs. Electronic crossmatch: computer-verified ABO compatibility substitute. In urgent situations: group O RBCs and group AB plasma are safe choices. 4. Direct Coombs test (DAT): detects antibodies or complement already coating patient's RBCs in vivo.<br><br><b>INDIRECT vs DIRECT COOMBS TEST</b><br><br>Direct Antiglobulin Test (DAT, Direct Coombs): detects in vivo sensitization - antibodies/complement coating RBCs in the patient. Positive in: autoimmune hemolytic anemia, hemolytic transfusion reactions, HDFN, drug-induced hemolysis. Indirect Antiglobulin Test (IAT, Indirect Coombs): detects free antibodies in serum. Used in: antibody screen, crossmatch, detection of maternal alloantibodies.<br><br><b>BLOOD COMPONENTS</b><br><br>Whole Blood: rarely used, replaced by component therapy. Shelf life 35 days at 1-6 degrees C.<br><br>Packed Red Blood Cells (pRBCs): 1 unit raises Hb by approximately 1 g/dL (Hct by 3%). Shelf life 35-42 days at 1-6 degrees C. Indications: Hb below 6 g/dL (almost always indicated), Hb above 10 g/dL (rarely indicated), Hb 6-10 g/dL (clinical judgment). Transfusion trigger: Hb 7-8 g/dL (restrictive strategy preferred).<br><br>Platelet Concentrates: obtained from pooled whole blood donations (4-6 units) or single-donor apheresis. Stored at room temperature (20-24 degrees C) with constant gentle agitation for up to 7 days. 1 unit raises platelet count by approximately 7-10 x 10e9/L. 10 units raise platelet count by approximately 100 x 10e9/L. Bacterial contamination is the 3rd leading cause of transfusion-related death. Storage at room temperature favors bacterial growth - shorter storage (4 days vs 5 days) preferred.<br><br>Fresh Frozen Plasma (FFP): frozen within 8 hours of donation. Contains all plasma proteins including labile factors V and VIII. PF24: frozen within 24 hours - 25% reduction in factor VIII. Thawed plasma stored at 1-6 degrees C for up to 5 days. Indications: INR above 2 with active bleeding, coagulopathy in massive transfusion, DIC, reversal of warfarin when PCC unavailable, specific factor deficiency when concentrates unavailable. Risks: TRALI, TACO, allergic or anaphylactic reactions.<br><br>Cryoprecipitate: prepared from thawed FFP. Rich in fibrinogen (250 mg per unit), factor VIII, von Willebrand factor, factor XIII, and fibronectin. Indications: fibrinogen deficiency (less than 100 mg/dL), DIC, von Willebrand disease (when DDAVP fails), hemophilia A (when factor VIII concentrate unavailable), factor XIII deficiency.<br><br>Granulocyte Concentrates: obtained by apheresis. Shelf life 24 hours. Used in severe neutropenia with life-threatening infections not responding to antibiotics.<br><br><b>SPECIAL BLOOD PRODUCTS</b><br><br>Leukoreduced blood: WBCs removed by filtration. Indications: prevention of febrile nonhemolytic reactions, CMV transmission prevention, HLA alloimmunization prevention, platelet refractoriness prevention. Irradiated blood: gamma irradiation (25 Gy) to prevent donor T lymphocytes from proliferating. Indication: prevention of transfusion-associated graft-versus-host disease (TA-GVHD) in immunocompromised hosts - bone marrow transplant, congenital immunodeficiency, neonates. Washed RBCs: saline-washed to remove plasma proteins. Indication: IgA deficiency (prevents anaphylaxis), paroxysmal nocturnal hemoglobinuria. CMV-negative blood: used in CMV-seronegative immunocompromised patients.<br><br><b>TRANSFUSION REACTIONS - OVERVIEW</b><br><br>Classified as: Immediate (within 24 hours) vs Delayed (after 24 hours). Immune vs Non-immune. Acute vs Chronic.<br><br><b>ACUTE HEMOLYTIC TRANSFUSION REACTION (AHTR)</b><br><br>Mechanism: preformed recipient IgM antibodies vs donor RBC antigens (ABO incompatibility most common). Complement activation causes intravascular hemolysis. Features: fever, shaking chills, flank or back pain, hemoglobinuria (red-brown urine), nausea, hypotension. Complications: DIC, shock, acute renal tubular necrosis, death. Lab: positive DAT, hemoglobinemia, hemoglobinuria, elevated LDH and bilirubin, decreased haptoglobin. Management: STOP transfusion immediately, IV fluids, maintain urine output, treat DIC and shock. Most common cause: clerical error (mislabeling or wrong patient identification).<br><br><b>DELAYED HEMOLYTIC TRANSFUSION REACTION (DHTR)</b><br><br>Onset: 3-14 days post-transfusion. Mechanism: anamnestic IgG antibody response to minor blood group antigens (Kidd, Duffy, Kell, Rh). Features: progressive anemia, jaundice, low-grade fever, positive DAT. May be severe if antibody fixes complement.<br><br><b>FEBRILE NONHEMOLYTIC TRANSFUSION REACTION (FNHTR)</b><br><br>Most common transfusion complication. Mechanism: recipient antibodies against donor WBC HLA antigens, or cytokines released from donor leukocytes during storage. Features: fever (temperature rise more than 1 degree C), chills, headache during or within 1-2 hours of transfusion. Management: STOP transfusion initially to rule out AHTR. Antipyretics (acetaminophen). Resume if hemolytic reaction excluded. Prevention: leukoreduction, prestorage filtration.<br><br><b>ALLERGIC TRANSFUSION REACTIONS</b><br><br>Mild (urticarial): IgE-mediated, most common (1-3% of transfusions). Features: urticaria, pruritus, no fever. Management: antihistamines, may continue transfusion after resolution. Severe (anaphylactic): IgG-mediated, occurs in IgA-deficient patients with anti-IgA antibodies. Features: bronchospasm, hypotension, angioedema, shock without fever. Management: STOP transfusion, epinephrine, supportive care. Prevention: washed RBCs, IgA-deficient plasma products.<br><br><b>TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD (TACO)</b><br><br>Leading cause of transfusion-related death (recently surpassed TRALI). Mechanism: volume overload from transfusion causing hydrostatic pulmonary edema (cardiogenic). Risk factors: elderly, cardiac disease, pulmonary disease, chronic renal failure, low body weight, rapid infusion rate. Features: dyspnea, orthopnea, cyanosis, hypertension, tachycardia, bilateral crackles, within 6 hours of transfusion. Chest X-ray: bilateral infiltrates, cardiomegaly, Kerley B lines, pleural effusion. BNP markedly elevated, PCWP elevated (more than 18 mmHg). Management: diuretics (furosemide), stop or slow transfusion, oxygen, upright positioning. Prevention: slow infusion, diuretics between units, single unit transfusion.<br><br><b>TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI)</b><br><br>Formerly leading cause of transfusion-related death. Mechanism: two-hit model - first hit is priming of recipient neutrophils (due to underlying illness). Second hit is transfused antibody (often anti-HLA class I or anti-HNA antibody) activating primed neutrophils in pulmonary vasculature - causing non-cardiogenic pulmonary edema. Most commonly associated with plasma-containing products: FFP, platelets, whole blood. Features: acute dyspnea, hypoxemia (PaO2/FiO2 below 300), bilateral pulmonary infiltrates, fever, hypotension within 6 hours of transfusion. Onset: rapid - within minutes to hours of transfusion. Chest X-ray: bilateral infiltrates WITHOUT cardiomegaly or Kerley B lines. PCWP normal (below 18 mmHg) or not indicative of fluid overload. BNP normal or mildly elevated. Management: STOP transfusion, supportive oxygen (high-flow O2, mechanical ventilation if needed), NO diuretics (worsens hypotension). No specific treatment. Prevention: use of male-donor plasma (females have higher anti-HLA antibodies due to pregnancy), leukoreduction.<br><br><b>TRALI vs TACO - KEY DIFFERENTIATING FEATURES</b><br><br>TRALI: non-cardiogenic edema, hypotension, normal or low CVP, PCWP below 18 mmHg, BNP normal, fever present, bilateral infiltrates without cardiomegaly, responds to fluids NOT diuretics, most common with FFP and platelets (multiparous female donors), mechanism is antibody-mediated neutrophil activation.<br><br>TACO: cardiogenic edema, hypertension, elevated CVP, PCWP above 18 mmHg, BNP markedly elevated, no fever, bilateral infiltrates with cardiomegaly and pleural effusions, responds to diuretics, most common in elderly-cardiac patients, mechanism is volume overload.<br><br><b>OTHER TRANSFUSION COMPLICATIONS</b><br><br>Transfusion-associated graft-versus-host disease (TA-GVHD): donor T lymphocytes engraft and attack recipient tissues. Features: pancytopenia, skin rash, hepatitis, diarrhea, high mortality (90%). Prevention: irradiation of blood products. Transfusion-transmitted infections: HIV 1 in 1.5 million, HCV 1 in 1 million, HBV 1 in 205,000, bacterial contamination most common (especially platelets). Post-transfusion purpura: severe thrombocytopenia 5-10 days after transfusion due to anti-HPA antibodies. Iron overload: hemosiderosis in chronically transfused patients - treat with deferasirox or deferoxamine. Hypothermia: use blood warmers in massive transfusion. Hypocalcemia: citrate toxicity in massive transfusion. Hyperkalemia: from stored blood RBC lysis. Dilutional coagulopathy: in massive transfusion.<br><br><b>HEMOLYTIC DISEASE OF FETUS AND NEWBORN (HDFN)</b><br><br>Cause: maternal IgG alloantibodies crossing placenta destroying fetal RBCs. Rh incompatibility: Rh-negative mother, Rh-positive fetus. First pregnancy rarely affected (initial sensitization produces IgM). Subsequent pregnancies: brisk IgG response causes HDFN. Concurrent ABO incompatibility PROTECTS against Rh sensitization (fetal RBCs cleared by maternal ABO antibodies before sensitizing). ABO incompatibility HDFN: now more common than Rh HDFN (due to RhIg prophylaxis). Occurs in group A or B infants of group O mothers. First-born can be affected (some group O mothers have natural IgG anti-A and anti-B). Usually milder - A and B antigens expressed on many non-RBC cells acting as sponge for antibody. Treatment: phototherapy, exchange transfusion, intrauterine transfusion. Prophylaxis: RhIg (anti-D immunoglobulin) to Rh-negative mothers at 28 weeks and within 72 hours post-delivery.<br><br><b>BLOOD GROUP ANALYSIS - IMPORTANT FACTS FOR EXAM</b><br><br>Bombay phenotype (Oh): complete absence of H antigen due to homozygous mutations in fucosyltransferase (FUT1) gene. Cannot express A, B, or H antigens. Have anti-H, anti-A, anti-B antibodies - can only receive Bombay blood. More common in India. Secretors vs non-secretors: 80% of population are secretors who secrete ABO antigens in saliva and other body fluids. Cold agglutinins: IgM antibodies reacting at 4 degrees C, associated with Mycoplasma pneumoniae infection and infectious mononucleosis. Warm agglutinins: IgG antibodies reacting at 37 degrees C, associated with autoimmune hemolytic anemia. Type and screen vs type and crossmatch: type and screen adequate for procedures with low transfusion probability. Massive transfusion protocol: transfuse pRBC, FFP, and platelets in 1:1:1 ratio.<br><br><b>HIGH-YIELD ONE-LINERS</b><br><br>Most common transfusion reaction: febrile nonhemolytic. Most common cause of AHTR: clerical error. Most common cause of transfusion-related death (historically TRALI, recently TACO). Cryoprecipitate contents: fibrinogen, factor VIII, vWF, factor XIII, fibronectin. FFP thawed within 8 hours, PF24 thawed within 24 hours. Platelets stored at room temperature for 7 days. Blood stored in CPDA-1 (citrate-phosphate-dextrose-adenine) anticoagulant-preservative. Citrate chelates calcium - used as anticoagulant in blood banking. Compatibility for plasma transfusion: opposite of RBC compatibility. Anti-HLA antibodies from multiparous women are associated with TRALI. Irradiated blood prevents TA-GVHD. Washed blood prevents allergic reactions in IgA deficiency. Leukoreduced blood prevents febrile reactions and CMV transmission.

What is the classification of blood group systems and what makes ABO the most clinically significant?	<b>DEFINITION AND CLASSIFICATION OF BLOOD GROUP SYSTEMS</b><br><br>A blood group system is defined as a set of red blood cell (RBC) antigens controlled by a single gene or a cluster of closely linked homologous genes. Over 30 blood group systems are recognized by the International Society of Blood Transfusion (ISBT). The most clinically significant are:<br><br><b>1. ABO System</b> - Most important. Antigens are carbohydrate structures on RBC surface glycoproteins and glycolipids. Natural (preformed) IgM antibodies exist against absent antigens - no prior sensitization needed. ABO incompatibility causes the most severe, potentially fatal transfusion reactions.<br><br><b>2. Rh System</b> - Second most important. Protein antigens (not carbohydrate). D antigen is most immunogenic. Antibodies are NOT naturally occurring - formed only after exposure. Critical in pregnancy (HDFN).<br><br><b>3. Other Clinically Significant Systems</b> - Kell (K antigen - highly immunogenic), Duffy (Fy - malaria resistance), Kidd (Jk - delayed hemolytic reactions), Lewis (Le - carbohydrate, plasma antigens adsorbed onto RBCs), MNS (M, N, S, s antigens), P system, I system (cold agglutinins in Mycoplasma and EBV).<br><br><b>Key Exam Fact</b> - ABO is the ONLY system with naturally occurring antibodies against absent antigens. All other clinically significant antibodies are immune (alloimmune) in origin - require prior exposure through transfusion or pregnancy.
What is the molecular basis and genetics of ABO blood group antigen expression?	<b>ABO ANTIGEN BIOCHEMISTRY AND GENETICS</b><br><br><b>Gene Location</b> - Chromosome 9q34. Single gene with three main alleles: A, B, and O.<br><br><b>H Antigen (Prerequisite)</b> - All individuals first form the H antigen, a fucosylated core glycan on RBC membrane glycoproteins and glycolipids. Formed by the FUT1 (H) gene on chromosome 19, which encodes alpha-2-L-fucosyltransferase. H antigen is the precursor structure for A and B antigens.<br><br><b>ABO Gene Products (Glycosyltransferases)</b> - A allele encodes enzyme that adds N-acetylgalactosamine (GalNAc) to H antigen - forming A antigen. B allele encodes enzyme that adds galactose (Gal) to H antigen - forming B antigen. O allele encodes a non-functional enzyme (single base deletion causing frameshift) - H antigen remains unmodified. AB individuals express both A and B transferase enzymes.<br><br><b>H Antigen Quantity by Blood Group (high to low)</b> - O greater than A2 greater than B greater than A2B greater than A1 greater than A1B. Blood group O individuals have the MOST H antigen.<br><br><b>Natural Antibodies</b> - Formed in first few months of life, stimulated by intestinal bacteria sharing carbohydrate structures with ABO antigens. Are IgM class - fix complement - cause intravascular hemolysis on incompatible transfusion. Anti-A and anti-B are present in individuals lacking the respective antigen.<br><br><b>Key Exam Fact</b> - A1 vs A2 subgroups: A1 antigens are more densely expressed and more reactive with anti-A. A2 individuals may have weak anti-A1 antibody causing compatibility issues.
What is the pathogenesis and molecular mechanism of Rh incompatibility and hemolytic disease of the fetus and newborn (HDFN)?	<b>Rh SYSTEM - PATHOGENESIS AND MOLECULAR MECHANISM</b><br><br><b>Rh Antigens</b> - Proteins (not carbohydrates) encoded by two closely linked genes on chromosome 1p: RHCE (encodes C, c, E, e antigens) and RHD (encodes D antigen). D antigen is the most immunogenic Rh antigen. Rh-positive = D antigen present. Rh-negative = absent RHD gene (deletion).<br><br><b>Sensitization Mechanism</b> - Rh-negative mother exposed to Rh-positive fetal RBCs (fetomaternal hemorrhage at delivery, or during pregnancy after 28 weeks when cytotrophoblast barrier breaks down). Primary immune response produces IgM anti-D - does NOT cross placenta - first pregnancy usually spared. Secondary response (subsequent Rh-positive pregnancy) produces high-titer IgG anti-D - CROSSES PLACENTA - causes HDFN.<br><br><b>HDFN Pathogenesis</b> - Maternal IgG anti-D coats fetal RBCs - opsonization - destruction by fetal splenic macrophages (extravascular hemolysis). Progressive fetal anemia causes: tissue ischemia, extramedullary hematopoiesis (hepatosplenomegaly), high-output cardiac failure, peripheral edema, ascites, hydrops fetalis.<br><br><b>Protective Effect of ABO Incompatibility</b> - Concurrent ABO incompatibility PROTECTS against Rh sensitization. Fetal Rh-positive RBCs that enter maternal circulation are rapidly destroyed by maternal anti-A or anti-B IgM isohemagglutinins before they can sensitize the mother to D antigen.<br><br><b>Prophylaxis</b> - RhIg (anti-D immunoglobulin, Rho-GAM) given to Rh-negative mothers at 28-32 weeks AND within 72 hours post-delivery. Mechanism: RhIg masks D antigenic sites on any fetal RBCs that entered maternal circulation - prevents long-lasting sensitization. Dose: 300 mcg covers up to 30 mL fetal whole blood or 15 mL fetal RBCs.
What are the high-yield associations and exam facts about the ABO blood group compatibility table?	<b>ABO BLOOD GROUP TABLE - HIGH-YIELD FACTS AND ASSOCIATIONS</b><br><br><b>Blood Group O</b> - Antigen on RBC: none (only H antigen). Antibodies in serum: anti-A (IgM) and anti-B (IgM). Universal DONOR for packed RBCs (no A or B antigens to react with recipient antibodies). Most common blood group worldwide. Has the MOST H antigen.<br><br><b>Blood Group AB</b> - Antigens on RBC: A and B. Antibodies in serum: NONE. Universal RECIPIENT for packed RBCs (no antibodies to react against donor RBCs). Universal DONOR for plasma and FFP (no antibodies to attack recipient RBCs). Rarest blood group in most populations.<br><br><b>Blood Group A</b> - Antigen: A. Antibody: anti-B.<br><br><b>Blood Group B</b> - Antigen: B. Antibody: anti-A.<br><br><b>Plasma Compatibility Rule</b> - OPPOSITE of RBC rule. Group O plasma (contains anti-A and anti-B) can only be given to group O recipients. Group AB plasma (contains no antibodies) = universal DONOR for plasma.<br><br><b>High-Yield Associations</b> - Blood group A: higher risk of gastric carcinoma and pancreatic cancer, higher risk of venous thromboembolism. Blood group O: higher risk of peptic ulcer disease (associated with H. pylori), lower risk of thromboembolic disease, lower risk of gastric cancer. Blood group A2 individuals: may develop clinically significant anti-A1 antibody.<br><br><b>Safe Emergency Transfusion</b> - If blood type unknown: give group O Rh-negative pRBCs and group AB plasma. Uncrossmatched O-negative blood acceptable in life-threatening hemorrhage.
What is the Bombay phenotype and what are its clinical and transfusion implications?	<b>BOMBAY PHENOTYPE (Oh) - NAMED SYNDROME AND HIGH-YIELD ASSOCIATIONS</b><br><br><b>Definition</b> - A rare blood group phenotype in which the individual COMPLETELY lacks H antigen on RBCs (and in secretions). Named because first discovered in Bombay (Mumbai), India in 1952 by Bhende.<br><br><b>Molecular Basis</b> - Homozygous loss-of-function mutations in the FUT1 (H) gene on chromosome 19, encoding alpha-2-L-fucosyltransferase. Without H antigen, neither A nor B antigens can be synthesized - even if the individual carries A or B alleles at chromosome 9.<br><br><b>Antibodies Produced</b> - Anti-H, anti-A, and anti-B - ALL three antibodies present. Anti-H is a potent IgM antibody that fixes complement and causes severe intravascular hemolysis.<br><br><b>Critical Transfusion Implication</b> - Bombay individuals can ONLY receive blood from other Bombay donors. They will react against ALL ABO blood group types including O, because all normal blood groups express H antigen. This makes them extremely difficult to transfuse in emergencies.<br><br><b>Epidemiology</b> - Incidence: 1 in 10,000 in India (especially Maharashtra), 1 in 1 million in Europe. More common in consanguineous families.<br><br><b>Diagnosis</b> - Forward grouping appears to be group O (no A or B antigens). Reverse grouping: anti-A, anti-B, and also anti-H reacts with O cells - which is NOT expected in true group O. Anti-H (Ulex europaeus lectin) fails to agglutinate Bombay RBCs (agglutinates group O cells normally).<br><br><b>Key Exam Fact</b> - Bombay phenotype individuals are true group O on forward typing but the DISCREPANCY between forward and reverse grouping should prompt testing with anti-H lectin.
What are the components of pretransfusion testing and what do they detect?	<b>PRETRANSFUSION TESTING - LAB FINDINGS AND DIAGNOSTIC CRITERIA</b><br><br><b>1. ABO and Rh Typing</b> - Forward (cell) grouping: patient RBCs tested against commercial anti-A and anti-B antisera. Reverse (serum) grouping: patient serum tested against known A1 and B reagent RBCs. Results must be concordant - discrepancy triggers investigation. Rh typing: patient RBCs tested with anti-D reagent.<br><br><b>2. Antibody Screen (Indirect Antiglobulin Test, IAT)</b> - Patient serum incubated with commercially prepared group O reagent RBCs expressing most clinically significant antigens. Detects unexpected (non-ABO) alloantibodies. Positive screen triggers antibody identification panel. Most significant detected antibodies: anti-D, anti-c, anti-K, anti-Jka, anti-Fya, anti-E.<br><br><b>3. Crossmatch</b> - Major crossmatch: recipient serum vs donor RBCs - most important, detects recipient antibodies reacting with donor cells. Minor crossmatch: donor plasma vs recipient RBCs - detects donor antibodies against recipient cells. Electronic (computer) crossmatch: replaces serologic crossmatch when two concordant ABO/Rh types are on record and antibody screen is negative. Immediate spin crossmatch: room temperature centrifugation only - detects ABO incompatibility but not all clinically significant antibodies.<br><br><b>4. Direct Antiglobulin Test (DAT)</b> - Not routine pretransfusion. Done when hemolytic reaction suspected. Detects IgG or C3 already coating patient RBCs in vivo. Positive in: AHTR, DHTR, HDFN, autoimmune hemolytic anemia, drug-induced hemolysis.<br><br><b>Emergency Situations</b> - When crossmatch cannot be completed: use group O Rh-negative uncrossmatched blood. If antibody identification cannot be completed: medical judgment on clinical urgency required.
How do you differentiate the Direct Antiglobulin Test (DAT) from the Indirect Antiglobulin Test (IAT) and what clinical conditions make each positive?	<b>DIRECT vs INDIRECT COOMBS TEST - DIFFERENTIATION</b><br><br><b>Principle of Antiglobulin Test</b> - Anti-human globulin (Coombs reagent) contains antibodies against human IgG and complement (C3d). It bridges IgG-coated RBCs to cause visible agglutination.<br><br><b>Direct Antiglobulin Test (DAT - Direct Coombs)</b> - Tests for IN VIVO sensitization. Patient RBCs are washed (to remove free serum antibodies) and then incubated directly with Coombs reagent. Positive result means antibodies or complement are ALREADY coating the patient's RBCs. Clinical conditions with positive DAT: acute hemolytic transfusion reaction (AHTR), delayed hemolytic transfusion reaction (DHTR), autoimmune hemolytic anemia (warm or cold), hemolytic disease of the fetus and newborn (HDFN), drug-induced immune hemolytic anemia (methyldopa, penicillin, cephalosporins), graft-vs-host disease.<br><br><b>Indirect Antiglobulin Test (IAT - Indirect Coombs)</b> - Tests for FREE antibodies in patient SERUM. Patient serum is incubated with reagent RBCs, then Coombs reagent is added. Positive result means antibodies in serum can coat (and potentially destroy) RBCs. Clinical uses: antibody screen (pretransfusion), crossmatch (major), detection of maternal alloantibodies in pregnancy, Rh typing (weak D testing).<br><br><b>Key Mnemonic</b> - Direct = already Done (coated in vivo). Indirect = In vitro test of serum.<br><br><b>Exam Trap</b> - A positive DAT does NOT always indicate hemolysis - must correlate with clinical and lab evidence of hemolysis (elevated LDH, indirect bilirubin, decreased haptoglobin, hemoglobinemia, hemoglobinuria).
What is the definition and classification of blood components used in transfusion medicine?	<b>BLOOD COMPONENTS - DEFINITION AND CLASSIFICATION</b><br><br><b>Definition</b> - Blood components are therapeutic preparations derived from whole blood by physical separation methods (centrifugation, filtration, apheresis). Component therapy replaced whole blood transfusion to allow specific targeted replacement and maximize utilization of each donation.<br><br><b>Classification by Origin</b> - From whole blood donation: pRBCs, platelet concentrates (random donor), FFP, cryoprecipitate. From apheresis (single donor): apheresis platelets, plasmapheresis products, granulocyte concentrates.<br><br><b>Major Blood Components</b> - Packed Red Blood Cells (pRBCs): shelf life 35-42 days at 1-6 degrees C (stored in CPDA-1 or additive solutions like AS-1, AS-3, AS-5). Raises Hb by 1 g/dL per unit in 70-kg adult. Platelet Concentrates: stored at 20-24 degrees C with gentle agitation for up to 7 days. Fresh Frozen Plasma (FFP): frozen within 8 hours, shelf life 1 year at -18 degrees C, thawed plasma usable 5 days at 1-6 degrees C. PF24: frozen within 24 hours. Cryoprecipitate: derived from thawed FFP, refrozen, shelf life 1 year. Granulocyte Concentrate: apheresis-derived, shelf life 24 hours at 20-24 degrees C.<br><br><b>Anticoagulant-Preservative Solutions</b> - CPDA-1 (citrate-phosphate-dextrose-adenine): shelf life 35 days. Additive solutions (AS-1 Adsol, AS-3, AS-5): shelf life 42 days. Citrate chelates calcium acting as anticoagulant. Dextrose and adenine maintain RBC metabolism and ATP levels.<br><br><b>Key Exam Fact</b> - 2,3-DPG decreases during RBC storage (stored blood has left-shifted O2 dissociation curve - reduced O2 delivery). Returns to normal 24 hours post-transfusion.
What are the storage requirements, bacterial contamination risk, and indications for platelet transfusion?	<b>PLATELET CONCENTRATES - STORAGE, COMPLICATIONS, AND CLINICAL USE</b><br><br><b>Preparation</b> - Random donor (pooled): 4-6 whole blood donations centrifuged - pooled into 1 therapeutic dose. Single-donor apheresis: harvested from one donor by apheresis machine - equivalent to 4-6 pooled units. Single-donor apheresis preferred to reduce HLA alloimmunization (less antigen exposure).<br><br><b>Storage</b> - 20-24 degrees C with continuous gentle agitation. Shelf life: up to 7 days (formerly 5 days). Room temperature storage necessary to preserve platelet function but INCREASES bacterial contamination risk dramatically.<br><br><b>Bacterial Contamination Risk</b> - Most common infectious complication of transfusion. Rate approximately 1 per 2,500 units. 25% of contaminated platelet transfusions cause septic reaction. Leading organisms: Staphylococcus epidermidis and Staphylococcus aureus (skin flora from venipuncture). Bacterial contamination is the 3rd leading cause of transfusion-related death. Shorter storage (4 days vs 5 days) significantly reduces risk.<br><br><b>Efficacy</b> - 1 random donor unit raises platelet count by 7-10 x 10e9/L per unit in a 70-kg adult. 1 apheresis unit (or 4-6 pooled units) raises count by approximately 30-60 x 10e9/L. Causes of poor platelet increment: splenomegaly, fever, sepsis, HLA alloimmunization, platelet refractoriness, active bleeding, DIC.<br><br><b>Indications</b> - Platelet count below 10,000 per mcL (prophylactic in stable patients). Below 20,000 with fever or infection. Below 50,000 for invasive procedure or minor surgery. Below 100,000 for neurosurgery or ophthalmologic surgery. Functionally impaired platelets regardless of count (aspirin toxicity, uremia, thrombasthenia).<br><br><b>Platelet Refractoriness</b> - Failure of platelet count to rise adequately post-transfusion. Immune cause: HLA alloimmunization (most common immune cause), anti-HPA antibodies. Non-immune cause: sepsis, DIC, splenomegaly, medications. Management of HLA alloimmunization: HLA-matched single-donor apheresis platelets.
How do you differentiate Fresh Frozen Plasma (FFP) from Cryoprecipitate in terms of composition and clinical indications?	<b>FFP vs CRYOPRECIPITATE - COMPOSITION AND INDICATIONS</b><br><br><b>Fresh Frozen Plasma (FFP)</b> - Composition: ALL plasma proteins including all coagulation factors (I, II, V, VII, VIII, IX, X, XI, XIII), natural anticoagulants (protein C, protein S, antithrombin III), fibrinogen (approximately 2-4 mg/mL), albumin, immunoglobulins. Volume: 200-250 mL per unit. Must be ABO-compatible. Thawed at 37 degrees C. Indications: multiple coagulation factor deficiency (liver disease, massive transfusion, DIC), vitamin K antagonist reversal (warfarin) when PCC unavailable, INR above 2 with active bleeding, specific factor deficiency when concentrate unavailable, thrombotic thrombocytopenic purpura (TTP) - plasma exchange with FFP.<br><br><b>Cryoprecipitate</b> - Prepared by thawing FFP at 1-6 degrees C and collecting the cold-insoluble precipitate. Concentrated in a small volume (10-15 mL per unit). RICH in: fibrinogen (150-250 mg per unit - main therapeutic source), factor VIII (80-100 IU per unit), von Willebrand factor (vWF), factor XIII, fibronectin. Indications: fibrinogen deficiency (fibrinogen below 100 mg/dL) - MAIN INDICATION, DIC with fibrinogen deficiency, von Willebrand disease (when DDAVP and vWF concentrates unavailable), hemophilia A (historical, now replaced by factor VIII concentrate), factor XIII deficiency, uremic bleeding (fibronectin content).<br><br><b>Key Differentiator</b> - FFP = broad coagulation support (ALL factors). Cryoprecipitate = targeted fibrinogen, factor VIII, vWF replacement. If the question mentions fibrinogen below 100 or DIC with hypofibrinogenemia - answer is CRYOPRECIPITATE. If PT and aPTT both prolonged with liver disease or warfarin reversal - answer is FFP.<br><br><b>Exam Trap</b> - Cryoprecipitate does NOT contain the vitamin K-dependent factors (II, VII, IX, X) in significant quantities. It does NOT correct the INR meaningfully.
What are the indications and mechanisms of action of special blood products: irradiated, leukoreduced, and washed blood?	<b>SPECIAL BLOOD PRODUCTS - INDICATIONS AND MECHANISMS</b><br><br><b>Leukoreduced Blood</b> - Method: pre-storage leukofiltration (preferred) or bedside filtration. Reduces WBC count to below 5 x 10e6 per unit. Indications and mechanisms: (1) Prevention of febrile nonhemolytic transfusion reactions - removes WBCs that release cytokines and HLA-reactive antibodies. (2) Prevention of CMV transmission - CMV resides in WBCs. (3) Prevention of HLA alloimmunization - reduces platelet refractoriness. (4) Prevention of transfusion-associated immunomodulation (TRIM). Prestorage leukoreduction superior to bedside - removes cytokines that accumulate during storage.<br><br><b>Irradiated Blood</b> - Method: gamma irradiation (minimum 25 Gy to product center) or X-ray irradiation. Destroys donor T lymphocyte proliferative capacity without affecting RBC or platelet function. Indication: prevention of Transfusion-Associated Graft-versus-Host Disease (TA-GVHD). Required in: bone marrow and stem cell transplant recipients, congenital immunodeficiency (SCID, DiGeorge), intrauterine transfusions, neonatal exchange transfusion, recipients of HLA-matched or directed donations from blood relatives, Hodgkin lymphoma patients, patients on purine analog drugs (fludarabine).<br><br><b>Washed Red Blood Cells</b> - Method: RBCs repeatedly washed with isotonic saline, removing virtually all plasma proteins. Reduces plasma protein content by 99%. Indications: IgA-deficient patients with anti-IgA antibodies (prevention of anaphylaxis), paroxysmal nocturnal hemoglobinuria (removes complement), severe recurrent allergic reactions, neonatal transfusion.<br><br><b>CMV-Seronegative Blood</b> - From CMV-seronegative donors. Used in: CMV-seronegative immunocompromised recipients when leukoreduced blood is unavailable. Note: leukoreduced blood is considered equivalent to CMV-safe.
What is the pathogenesis and molecular mechanism of Acute Hemolytic Transfusion Reaction (AHTR)?	<b>ACUTE HEMOLYTIC TRANSFUSION REACTION - PATHOGENESIS AND MECHANISM</b><br><br><b>Definition</b> - Hemolysis of transfused donor RBCs by preformed recipient antibodies occurring during or within 24 hours of transfusion.<br><br><b>Most Common Cause</b> - ABO incompatibility due to clerical error (mislabeled specimen, wrong patient identification, incorrect blood unit administered). NOT an error in blood banking - the error is administrative.<br><br><b>Mechanism - Intravascular Hemolysis</b> - Step 1: Recipient preformed IgM antibodies (anti-A or anti-B) bind to incompatible donor RBCs immediately on transfusion. Step 2: IgM efficiently activates the CLASSICAL complement pathway (C1 - C4 - C2 - C3 - C5-C9 membrane attack complex). Step 3: Complement activation proceeds to completion (C5b-C9 MAC) - causes INTRAVASCULAR hemolysis - direct osmotic lysis of donor RBCs within circulation. Step 4: Hemoglobin released - hemoglobinemia and hemoglobinuria (red-brown or cola-colored urine). Step 5: Free hemoglobin is toxic to renal tubular cells - causes acute tubular necrosis and renal failure. Step 6: Massive release of inflammatory cytokines (TNF, IL-1, IL-6) - systemic inflammatory response, fever, hypotension, shock. Step 7: Tissue factor release from hemolyzed RBCs and endothelial activation triggers DIC - consumption of clotting factors - paradoxical bleeding in setting of widespread thrombosis.<br><br><b>Minor Blood Group Antigen AHTR</b> - Caused by IgG alloantibodies (Kidd, Duffy, Kell, Rh system). Complement activation may be incomplete - causes extravascular hemolysis (phagocytosis by splenic macrophages). Less severe but can be significant if complement fixed.<br><br><b>Key Pathology Exam Fact</b> - AHTR due to ABO incompatibility = IgM + complement + INTRAVASCULAR hemolysis. DHTR = IgG + incomplete complement + EXTRAVASCULAR hemolysis.
What are the clinical features, lab findings, and management of Acute Hemolytic Transfusion Reaction (AHTR)?	<b>AHTR - CLINICAL FEATURES, LAB FINDINGS, AND MANAGEMENT</b><br><br><b>Clinical Features (onset within minutes to hours)</b> - Fever, shaking chills (most common early signs). Flank pain or back pain (due to renal ischemia from hemoglobin precipitation in tubules). Burning sensation at infusion site. Hypotension, tachycardia. Hemoglobinuria - red-brown or cola-colored urine (pathognomonic). Nausea, vomiting, facial flushing. In anesthetized patients: unexplained hypotension, hemoglobinuria, diffuse oozing from surgical field (DIC) may be ONLY signs.<br><br><b>Laboratory Findings</b> - Pink or red serum (hemoglobinemia). Red-brown urine (hemoglobinuria). Positive Direct Antiglobulin Test (DAT). Elevated LDH, elevated indirect bilirubin, elevated plasma hemoglobin. Decreased haptoglobin (haptoglobin binds free hemoglobin - depleted). Falling hematocrit. Prolonged PT and aPTT, low fibrinogen, elevated D-dimer (DIC). Elevated serum creatinine (renal failure). Elevated plasma free hemoglobin above 25 mg/dL is diagnostic of significant intravascular hemolysis.<br><br><b>Management</b> - IMMEDIATE STOP of transfusion (most important first step). Maintain IV access - infuse normal saline aggressively. Maintain urine output above 1 mL/kg/hr - may use furosemide or mannitol. Send: blood and urine samples, remaining blood unit and tubing to blood bank. Treat DIC with FFP, cryoprecipitate, platelets as needed. Treat shock with vasopressors if needed. Dialysis for acute renal failure if urine output fails to improve. Notify blood bank immediately for investigation (DAT, repeat ABO typing, clerical check).<br><br><b>Prognosis</b> - Mortality directly correlates with volume of incompatible blood transfused. Even 10-30 mL can be fatal. Immediate recognition and stopping transfusion is critical.
What is the etiology, pathogenesis, and prevention of Febrile Nonhemolytic Transfusion Reaction (FNHTR)?	<b>FEBRILE NONHEMOLYTIC TRANSFUSION REACTION - ETIOLOGY AND PREVENTION</b><br><br><b>Definition</b> - Fever (temperature rise of 1 degree C or more above pre-transfusion baseline) during or within 4 hours of transfusion, in absence of hemolysis, bacterial contamination, or other cause. MOST COMMON transfusion reaction overall.<br><br><b>Etiology and Pathogenesis</b> - TWO mechanisms: (1) Recipient alloantibodies (anti-HLA or anti-HNA antibodies formed from previous transfusions or pregnancies) react with donor WBC antigens - cytokine release - fever and chills. (2) Cytokines (IL-1, IL-6, IL-8, TNF-alpha) accumulate in blood product during storage from donor leukocytes - infused preformed cytokines directly cause fever. Mechanism 2 is more important for platelets (stored at room temperature, more cytokine accumulation).<br><br><b>Clinical Features</b> - Fever, chills, rigors, headache, malaise during or within 1-4 hours of transfusion. No hypotension, no hemoglobinuria, no back pain. Self-limiting. Must distinguish from AHTR (which can also present with fever and chills) - the difference is absence of hemolysis markers.<br><br><b>Management</b> - STOP transfusion initially (rule out AHTR - it can be fatal). Investigate for hemolysis: DAT, repeat ABO type, urinalysis. Administer acetaminophen (antipyretics - avoid aspirin in thrombocytopenic patients). Do NOT give meperidine routinely for rigors - use only if severe chills. May RESUME transfusion once AHTR ruled out.<br><br><b>Prevention</b> - Leukoreduction (pre-storage preferred over bedside) - addresses BOTH mechanisms. Pre-medication with acetaminophen reduces recurrence but NOT recommended routinely for first episode. Washed RBCs for recurrent severe FNHTR.<br><br><b>Key Exam Fact</b> - FNHTR is the most common transfusion reaction but is a DIAGNOSIS OF EXCLUSION - AHTR must be ruled out first in every febrile reaction.
How do you classify and differentiate mild allergic transfusion reactions from severe anaphylactic transfusion reactions?	<b>ALLERGIC TRANSFUSION REACTIONS - CLASSIFICATION AND DIFFERENTIALS</b><br><br><b>Classification</b> - Two types based on severity and mechanism:<br><br><b>1. Mild Urticarial Reaction (Most Common Allergic Reaction)</b> - Incidence: 1-3% of all transfusions. Mechanism: IgE-mediated (type I hypersensitivity) - recipient IgE antibodies against plasma proteins in donor blood product - mast cell degranulation - histamine release. Features: urticaria (hives), pruritus, erythema, NO fever, NO hypotension, NO bronchospasm. Onset: during transfusion. Management: STOP transfusion, administer diphenhydramine (antihistamine). After symptoms resolve completely, may CAUTIOUSLY RESUME transfusion. Prevention: pre-medication with antihistamine for patients with history of recurrent allergic reactions.<br><br><b>2. Severe Anaphylactic Reaction</b> - Incidence: rare (1 in 20,000 to 50,000 transfusions). Mechanism: IgG-mediated. Occurs predominantly in PATIENTS WITH IgA DEFICIENCY who have developed anti-IgA antibodies (IgG class) from prior exposure. Transfused IgA in donor plasma triggers severe systemic reaction. Features: bronchospasm, stridor, urticaria, angioedema, hypotension, tachycardia, shock. CRITICALLY - NO FEVER (distinguishes from AHTR and septic reaction). Onset: within seconds to minutes of starting transfusion. Management: STOP transfusion IMMEDIATELY, NEVER resume. Epinephrine 0.5 mg IM (first-line). IV fluids for hypotension. Antihistamines and corticosteroids (adjuncts only). Prevention: use washed RBCs (removes plasma proteins including IgA), IgA-deficient donor blood products, pre-medication with steroids and antihistamines.<br><br><b>Key Differentiator</b> - Anaphylaxis: NO fever, NO hemoglobinuria, immediate onset, IgA-deficient patient. AHTR: fever, back pain, hemoglobinuria. Septic reaction: high fever, hypotension, rigors.
What is the two-hit pathogenesis model of Transfusion-Related Acute Lung Injury (TRALI)?	<b>TRALI - TWO-HIT PATHOGENESIS MODEL</b><br><br><b>Definition</b> - Non-cardiogenic pulmonary edema occurring during or within 6 hours of transfusion of any blood product. Formerly the leading cause of transfusion-related mortality.<br><br><b>Two-Hit Model (Accepted Pathogenesis)</b> - Hit 1 (Recipient Priming): Underlying patient condition causes sequestration and PRIMING of neutrophils in the pulmonary microvasculature. Priming conditions include: sepsis, surgery, trauma, cytokine storm, mechanical ventilation, massive transfusion, prior infection. Primed neutrophils are in a heightened activation state but have not yet degranulated.<br><br>Hit 2 (Transfusion Trigger): Transfused blood product contains: (a) Anti-HLA class I or class II antibodies from donor (most common - from multiparous female donors or multiply transfused donors) OR (b) Anti-human neutrophil antigen (anti-HNA) antibodies OR (c) Biologically active lipids and cytokines from stored blood (lipid-2nd hit hypothesis). These transfused antibodies bind to MHC/HLA antigens on primed recipient neutrophils in pulmonary vasculature - causing explosive neutrophil activation, degranulation, and release of reactive oxygen species and proteases - massive endothelial damage - increased capillary permeability - non-cardiogenic pulmonary edema (protein-rich, inflammatory fluid floods alveoli).<br><br><b>Blood Products Most Commonly Implicated</b> - FFP (highest plasma volume), platelets, whole blood. Any plasma-containing product. Risk highest with multiparous female donors (40% of women develop anti-HLA antibodies through pregnancy).<br><br><b>Prevention</b> - Universal male-only plasma donation policy (reduces anti-HLA antibody-containing plasma). Deferral of multiparous female plasma donors. Leukoreduction (reduces lipid mediators). Recipient risk stratification.<br><br><b>Key Exam Fact</b> - TRALI is caused by DONOR antibodies attacking RECIPIENT neutrophils. AHTR is caused by RECIPIENT antibodies attacking DONOR RBCs.
What is the pathogenesis, clinical features, and management of Transfusion-Associated Circulatory Overload (TACO)?	<b>TACO - PATHOGENESIS, CLINICAL FEATURES, AND MANAGEMENT</b><br><br><b>Definition</b> - Acute pulmonary edema caused by hydrostatic fluid overload from blood product transfusion. Currently the LEADING cause of transfusion-related death (surpassed TRALI in recent years).<br><br><b>Pathogenesis</b> - Transfusion of blood products increases intravascular volume. In susceptible patients with limited cardiac reserve, the increased preload exceeds the heart's ability to compensate - left ventricular failure - elevated left atrial pressure - pulmonary venous hypertension - increased pulmonary capillary hydrostatic pressure - CARDIOGENIC (hydrostatic) pulmonary edema (fluid transudate leaks into alveoli). Fluid is protein-poor (low protein transudate) unlike TRALI (protein-rich exudate).<br><br><b>Risk Factors</b> - Elderly patients, pre-existing cardiac failure, left ventricular dysfunction, chronic renal failure, pulmonary hypertension, low body weight (less than 50 kg), hypoalbuminemia, rapid infusion rate, large volume transfusion, positive fluid balance.<br><br><b>Clinical Features</b> - Onset within 6 hours of transfusion start. Acute dyspnea, orthopnea, cyanosis. HYPERTENSION (key distinguishing feature from TRALI - TRALI causes HYPOTENSION). Tachycardia, S3 gallop, bilateral crackles. Peripheral edema, elevated JVP. Chest X-ray: bilateral alveolar infiltrates WITH cardiomegaly, Kerley B lines, pleural effusions, vascular redistribution (upper lobe diversion).<br><br><b>Lab Findings</b> - BNP markedly elevated (often above 250 pg/mL or 1.5-fold rise from pre-transfusion). PCWP elevated (above 18 mmHg). Central venous pressure elevated. Hypoxemia on ABG.<br><br><b>Management</b> - Stop or slow transfusion. Upright positioning. Supplemental oxygen. IV furosemide (diuretics - first-line). Vasodilators if needed. Phlebotomy in extreme cases.<br><br><b>Prevention</b> - Transfuse single unit at a time in high-risk patients. Slow infusion rate (2 mL/kg/hr). Give furosemide between units. Avoid unnecessary transfusions.
How do you differentiate TRALI from TACO clinically, radiologically, and by laboratory parameters?	<b>TRALI vs TACO - COMPREHENSIVE DIFFERENTIATION</b><br><br><b>TRALI</b> - Pathogenesis: non-cardiogenic pulmonary edema from neutrophil-mediated endothelial damage (antibody-mediated). Blood pressure: HYPOTENSION (or unchanged). Temperature: FEVER present. Onset: within 6 hours - often within 1-2 hours. Fluid status: euvolemic or hypovolemic. JVP/CVP: normal or low. PCWP: below 18 mmHg (non-cardiogenic). BNP: normal or minimally elevated. Chest X-ray: bilateral infiltrates WITHOUT cardiomegaly, NO Kerley B lines, NO pleural effusions (or minimal), NO upper lobe diversion. Pleural fluid: protein-rich EXUDATE (high protein, high LDH, inflammatory cells - neutrophils). Donor history: multiparous female donor or multiply transfused donor (anti-HLA antibodies). Treatment: STOP transfusion, supportive oxygen, mechanical ventilation if needed - NO DIURETICS (worsen hypotension). Diuretics contraindicated. Resolution: within 48-96 hours with supportive care. Mortality: 5-10%.<br><br><b>TACO</b> - Pathogenesis: cardiogenic pulmonary edema from volume overload. Blood pressure: HYPERTENSION (key differentiator). Temperature: no fever. Onset: during or within 6 hours. Fluid status: volume overloaded. JVP/CVP: elevated. PCWP: above 18 mmHg (cardiogenic). BNP: markedly elevated (above 250 pg/mL or 1.5x pre-transfusion rise). Chest X-ray: bilateral infiltrates WITH cardiomegaly, Kerley B lines, pleural effusions, upper lobe blood diversion. Pleural fluid: protein-poor TRANSUDATE. Patient profile: elderly, cardiac disease, renal failure. Treatment: STOP or slow transfusion, IV DIURETICS (furosemide) - first-line treatment.<br><br><b>Single Most Important Differentiator</b> - Hypertension and elevated BNP and elevated PCWP = TACO. Hypotension and normal BNP and normal PCWP = TRALI.
What are the pathogenesis and treatment of hemolytic disease of the fetus and newborn (HDFN)?	<b>HDFN - PATHOGENESIS, CLINICAL FEATURES, AND TREATMENT</b><br><br><b>Definition</b> - Immune hemolytic anemia in the fetus or newborn caused by maternal IgG alloantibodies crossing the placenta and destroying fetal RBCs expressing the corresponding antigen.<br><br><b>Causes in Decreasing Clinical Severity</b> - Rh (D antigen) incompatibility: Rh-negative mother, Rh-positive fetus. Most severe form - can cause hydrops fetalis. NOW LESS COMMON due to RhIg prophylaxis. ABO incompatibility: CURRENTLY THE MOST COMMON CAUSE (since Rh prophylaxis). Group O mother with group A or B infant. Usually MILD - A and B antigens expressed on many non-RBC tissues (sponge effect reduces free antibody targeting RBCs). Firstborn CAN be affected (some group O mothers have natural IgG anti-A or anti-B without sensitization). Other Rh antigens: anti-c (most clinically significant after anti-D), anti-E, anti-C. Kell system: anti-K - unique mechanism - suppresses erythropoiesis in addition to causing hemolysis - severe anemia with LOW reticulocyte count (unlike Rh HDFN which has high reticulocytes).<br><br><b>Clinical Features</b> - Jaundice within 24 hours of birth (pathological - NOT physiological). Anemia, pallor. Hepatosplenomegaly (extramedullary hematopoiesis). Hydrops fetalis (severe): generalized edema, ascites, pleural effusion, pericardial effusion - from fetal high-output cardiac failure.<br><br><b>Diagnosis</b> - Positive DAT on cord blood (IgG coating fetal RBCs). Maternal antibody screen positive. Indirect bilirubin elevated. Anemia, reticulocytosis (except Kell).<br><br><b>Treatment</b> - Phototherapy (converts unconjugated bilirubin to water-soluble form). Exchange transfusion (remove sensitized RBCs and bilirubin, provide antigen-negative RBCs). Intrauterine transfusion (for severe fetal anemia detected by MCA Doppler). IVIG in severe cases.<br><br><b>Prophylaxis</b> - RhIg (Rho-GAM) 300 mcg IM at 28 weeks and within 72 hours of delivery of Rh-positive baby. Also given after: abortion, ectopic pregnancy, amniocentesis, chorionic villus sampling, abdominal trauma.
What are the complications of chronic transfusion therapy and the pathogenesis and management of TA-GVHD, post-transfusion purpura, and iron overload?	<b>TRANSFUSION COMPLICATIONS - TA-GVHD, POST-TRANSFUSION PURPURA, AND IRON OVERLOAD</b><br><br><b>Transfusion-Associated Graft-versus-Host Disease (TA-GVHD)</b> - Pathogenesis: donor T lymphocytes in blood product engraft in immunocompromised recipient - recognize host tissues as foreign - attack host tissues including skin, gut, liver, and bone marrow. Bone marrow destruction causes PANCYTOPENIA - the hallmark distinguishing TA-GVHD from solid organ transplant GVHD (which spares bone marrow). Features: onset 4-30 days post-transfusion, maculopapular skin rash, diarrhea, hepatitis, fever, PANCYTOPENIA. Mortality: greater than 90% (virtually always fatal - no effective treatment). Risk factors: immunocompromised recipients, HLA-matched directed donations, blood from first-degree relatives, intrauterine recipients, neonates. Prevention: IRRADIATION of blood products (25 Gy minimum). Leukoreduction is NOT sufficient to prevent TA-GVHD. NOTE: pathogen reduction (Mirasol, Intercept) may be considered equivalent to irradiation.<br><br><b>Post-Transfusion Purpura (PTP)</b> - Pathogenesis: severe thrombocytopenia occurring 5-10 days after transfusion due to alloantibodies against platelet-specific antigens (usually anti-HPA-1a). Paradoxically, the patient destroys THEIR OWN platelets along with donor platelets (bystander mechanism). More common in multiparous women. Features: sudden severe thrombocytopenia (platelet count below 10,000), bleeding risk. Treatment: IVIG (first-line, restores platelet count in 1-4 days), plasmapheresis (alternative).<br><br><b>Transfusion-Related Iron Overload (Hemosiderosis)</b> - Each unit pRBCs contains approximately 200-250 mg elemental iron. Normal daily iron excretion: 1-2 mg. Patients receiving more than 20 units lifetime (thalassemia, sickle cell, MDS) develop iron overload. Iron deposits in: heart (cardiomyopathy - main cause of death), liver (cirrhosis), endocrine glands (diabetes, hypogonadism, hypothyroidism). Serum ferritin above 1000 mcg/L indicates significant overload. Treatment: iron chelation therapy - deferoxamine (parenteral, first-line in children under 2 years), deferasirox (oral, preferred in older patients and adults), deferiprone (oral, best for cardiac iron).